Company
Kymera Therapeutics, Inc.
Headquarters: Watertown, MA, United States
Employees: 141
CEO: Dr. Nello Mainolfi M.D., Ph.D.
Market Cap
$2.86 Billion
USD as of Jan. 1, 2025
Kymera Therapeutics, Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Financials
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | $87.6 M |
| EBITDA | $-190,490,000 |
| Gross Profit TTM | $-133,838,000 |
| Profit Margin | -191.26% |
| Operating Margin | -1927.93% |
| Quarterly Revenue Growth | -20.90% |
Stocks & Indices
Kymera Therapeutics, Inc. has the following listings and related stock indices.
Stock: NASDAQ: KYMR wb_incandescent